Discover investment opportunities in Medical Device Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Medical Device Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Medical Device Stocks using our Smart AI Filter.
9 stocks found for "Medical Device Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.41 | ±20.0% | 11.2 | 2.36% | |||
2.11 | ±79.8% | -2.3 | 0.00% | |||
0.51 | ±20.1% | 29.1 | 0.86% | |||
0.64 | ±28.2% | 69.3 | 0.00% | |||
0.41 | ±18.7% | 37.4 | 0.00% | |||
0.98 | ±39.0% | 19.2 | 0.00% | |||
0.70 | ±21.9% | 10.9 | 1.04% | |||
1.00 | ±35.9% | 31.3 | 0.00% | |||
0.90 | ±53.5% | 7.9 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What factors contribute to the appeal of medical device stocks like MDT and BSX?
A: Medical device stocks such as Medtronic (MDT) and Boston Scientific (BSX) are often favored for their strong growth potential. These companies benefit from an aging population, increasing chronic disease prevalence, and advancements in medical technology. Investors may view these stocks as opportunities for consistent demand and innovation.
Q: How do historical performances of ISRG and SYK influence their investment potential?
A: Intuitive Surgical (ISRG) and Stryker (SYK) have historically demonstrated robust performance, driven by breakthroughs in surgical robotics and orthopedic devices. Their track records of revenue growth and market leadership position can attract investors seeking companies with sustained competitive advantages.
Q: Are medical device stocks like ZBH and ABT suitable for income-focused investors?
A: Zimmer Biomet (ZBH) and Abbott Laboratories (ABT) pay dividends, though yields can vary. Income-focused investors might find it valuable to assess payout ratios and historical dividend consistency, as these factors impact the reliability of income from these stocks.
Q: What sector-specific risks could impact the performance of EW and BAX?
A: Edwards Lifesciences (EW) and Baxter International (BAX) face sector-specific risks including regulatory challenges, product recalls, and competition from new entrants. These risks can influence market performance, making thorough due diligence essential for investors.
Q: How might TMO's position in the diagnostics sector affect its stock performance during economic cycles?
A: Thermo Fisher Scientific (TMO), known for its role in diagnostics, might demonstrate resilience during economic downturns as diagnostic demand can remain consistent. However, economic cycles may influence research budgets and capital expenditure from laboratories, affecting sales.
Q: What factors should be considered when assessing HRC's competitive position in the medical device industry?
A: Hill-Rom Holdings (HRC) stands out in patient care and mobility solutions. Competitive assessments should include market share, innovation rate, and customer base stability. Partnerships with healthcare providers can enhance HRC's industry positioning.
Last year, Morgan Stanley upgraded its outlook for the U.S. MedTech sector to 'Attractive,' believing the concerns around GLP-1s were already reflected in stock prices and that fundamentals were strong.
Read more